Get in touch

Submit

Thank you

Pharmaceutical products can often attract patent protection.  This affords the owner a monopoly in that product; however, the monopoly will only last a fixed period, after which it is open season for competitors.  Choosing a strong, resilient brand name will help foster brand loyalty and encourage customers to continue purchasing your product even when other (potentially cheaper) products have become available.  Obtaining a trade mark registration for your brand name allows you to stop other businesses cashing in on your brand loyalty/success.  It also affords protection against inferior products tainting your hard-earned brand recognition.

 

Pharmaceutical trade marks require regulatory approval.  In the UK, the appropriate body is the Medicines and Healthcare Products Regulatory Agency (MHRA).  The MHRA will reject a proposed pharmaceutical brand name if they believe that: (i) consumers will confuse the chosen name with the name of an existing medicine; (ii) the chosen name is misleading; or (iii) the chosen name is considered unsafe.  Regulatory approval is required before a pharmaceutical product can be sold under the chosen name.

 

The MHRA’s assessment of the trade mark is entirely separate to the assessment undertaken by the UK Intellectual Property Office (UKIPO) if/when a UK trade mark application is filed.  The UKIPO will reject a trade mark application if it considers the mark descriptive or non-distinctive (e.g. “strong medicine” or “cough mixture plus”) – such terms are to be kept free for all to use.  If the UKIPO decides that the brand name meets this threshold it will publish it for opposition purposes – this is where an objection can be brought by the owner of an earlier conflicting right.  It is strongly advisable to conduct a trade mark search prior to selecting a brand name so that you have an idea of the risk profile of the mark and the likelihood of a third party objection being raised. 

 

A trade mark registration is generally valid for 10 years and can be renewed for successive 10 year period, potentially indefinitely.  However, bear in mind that ownership of a trade mark registration does not give you the right to sell a pharmaceutical product under the registered name, regulatory approval is required for that.

 

Recommendations in light of the above:

  • Kick-off the naming process as early as possible
  • Pick distinctive, memorable trade marks, not ones that describe your products (or characteristics)
  • Consider multiple potential names, or at least have some fall-back alternatives in mind
  • Conduct searches of the MHRA and trade mark registers at an early stage
  • Subject to the results of the searches, apply to register your trade marks

 

MoreThatchers Triumphs in Trade Mark Trial

21.01.2025

Thatchers Triumphs in Trade Mark Trial

On 20 January 2025, the Court of Appeal delivered a significant judgment in the case of Thatchers Cider Company Limited v. Aldi Stores Limited, ruling in favour of Thatchers in its trade mark infringement claim against Aldi. This decision overturned a previous High Court ruling from January 2024, which had dismissed Thatchers' claims.

MoreCase Law Review: Board of Appeal Decision T 1741/22

29.04.2025

Case Law Review: Board of Appeal Decision T 1741/22

Patent applications related to data processing often fall foul of the EPO’s exclusions on “mathematical methods”. Applicants in the MedTech space in particular may find it far easier to protect the hardware in their wearable devices and tools than to protect the software that processes and analyses that data. A recent board of appeal decision T 1741/22 seems to contradict the Guidelines for Examination and previous Board of Appeal decisions. This decision may shed some light on how the EPO may approach these data processing applications in future.

Get in touch

Submit

Thank you